DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ZENITH DRUGS LIMITED (ZENITHDRUG) share price today?

ZENITH DRUGS LIMITED (ZENITHDRUG) is trading at ₹51 on the NSE, up 1.80% on the day. Source: DocStoX.

What is the PE ratio of ZENITH DRUGS LIMITED?

ZENITH DRUGS LIMITED has a price-to-earnings (PE) ratio of 12.2 in the Healthcare sector.

What is the market capitalisation of ZENITH DRUGS LIMITED?

ZENITH DRUGS LIMITED has a market capitalisation of approximately ₹0 crore.

ZENITH DRUGS LIMITED

ZENITHDRUG·NSE·Healthcare

₹51.00▲ +0.90 (+1.80%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹49.20

₹51.00

52W₹33

₹7641%

Open

₹50.15

High

₹51.00

Low

₹49.20

Prev Close

₹50.10

Volume

6.4K

VWAP

₹50.50

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

12.20Cheap

P/B Ratio

1.14

EPS

₹4.18

Book Value

₹43.69

ROE

5.77%Weak

ROCE

13.00%Decent

Dividend Yield

1.01%

Debt / Equity

0.73Moderate

Face Value

₹10.00

52W High

₹76.00

52W Low

₹33.30

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatMedium uncertainty

Fair value estimate

₹53

▲ 4.0%upside

Trading at ₹51 — 4% below our estimate

BearFair valueBull

₹45₹53₹64

/100

Business quality — Watch the fundamentals

Growth 23Profitability 11Efficiency 13Valuation 79

Plain English

Our view

A steady, established business
Reasonably priced at 12× earnings
Weak returns on equity (6%)

Strengths

Reasonably priced at 12× earnings
Promoters hold a controlling stake

Risks

Weak returns on equity (6%)
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

15% ROE fading to 13% over ~10 yrs, on ₹44 book

₹50

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹64

Analyst target

No analyst coverage

—

Blended fair value₹53

What the numbers say

Investment thesis

Bull case

Reasonably priced at 12× earnings
Promoters hold a controlling stake

Bear case

Weak returns on equity (6%)
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

12.2Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

5.8%Weak

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.73Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

1.14

EPS

₹4.18

Div Yield

1.01%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 12.2×

Growth

Steady

+14% rev CAGR

Profitability

Modest

5.8% ROE

Financial health

Comfortable

D/E 0.73

Momentum

N/A

No technicals

Today

Trading activity

Delivery %75.0%

Turnover₹3.23L Cr

Trades8

VWAP₹50.50

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.2%

+18.9%

10Y

—

Profit

-7.6%

+5.6%

10Y

—

EPS

—

10Y

—

Profile

Pros

Stock is trading at 1.12 times its book value

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 12.4% over last 3 years.
Earnings include an other income of Rs.4.88 Cr.
Company has high debtors of 156 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

70%

Promoter

Promoters

70.0%0.00

Public

24.7%-0.52

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

5.3%

Total shareholders

1,435-31 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter69.98%

Public24.73%

Others5.29%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing and trading of medicines[1]